ArticleClinical rheumatology2026
Inverse association between metabolic dysfunction-associated steatotic liver disease and incident rheumatoid arthritis in middle-aged adults with chronic hepatitis B.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionChronic hepatitis B (CHB) frequently coexists with metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to determine whether MASLD is a risk factor for incident rheumatoid arthritis among middle-aged patients with CHB in a real-world setting.
methodA population-based cohort study was conducted using the Korean National Health Insurance Service, including 114,425 middle-aged CHB individuals (aged 40-65 years) classified as having either MASLD or non-SLD. Cox proportional hazards regression and Fine-Gray subdistribution hazard models were applied to assess RA risk, accounting for all-cause mortality as a competing event. All patients were followed up until RA, death, or January 31, 2022.
resultsDuring 792,777 person-years of follow-up, 867 incident RA cases were identified. CHB patients with MASLD had a significantly lower risk of RA development compared to non-SLD participants (subdistribution hazard ratio [SHR], 0.82; 95% CI, 0.69-0.97). This effect was more obvious among younger aged patients (< 50 years). Additionally, higher daily alcohol consumption (1 g/day) was associated with an increased adjusted SHR for RA among all middle-aged CHB patients (1.007; 95% CI, 1.003-1.012).
conclusionsIn middle-aged patients with CHB, the presence of MASLD was associated with a lower risk of developing RA. However, the underlying mechanisms remain unclear, and residual confounding by CHB severity, liver disease stage, or antiviral treatment may have contributed to the observed association. Further studies are warranted to clarify these potential mechanisms linking CHB, MASLD, and RA risk. Key Points • In a nationwide Korean cohort of 114,425 middle-aged adults with CHB, MASLD was associated with a lower incidence of seropositive rheumatoid arthritis compared with non-steatotic liver disease. • In patients with CHB, MASLD may represent a distinct clinical state whose meaning could differ from standalone MASLD because it may be intertwined with the CHB disease stage and immune milieu.
Indexed as
Identifiers
42399574What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.